+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Viatris Inc (VTRS) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 78 Pages
  • April 2023
  • GlobalData
  • Viatris
  • ID: 4189010
Viatris Inc (VTRS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Viatris Inc (Viatris) is a healthcare company, which develops, licenses, manufactures, markets and distributes generics and branded medicines, and consumer healthcare products. It offers pharmaceuticals in multiple forms for various disease conditions related to respiratory, cardiovascular, central nervous system (CNS) system and allergy, skin disease, and cancer. It also offers anti- retrovirals, anaphylaxis products, and active pharmaceutical ingredients (APIs). The company sells its products to retail pharmacy chains, wholesalers and distributors, group purchasing organizations, drug store chains, independent pharmacies, drug manufacturers, institutions, and public and governmental agencies. The company markets its products in various countries. Viatris is headquartered in Canonsburg, Pennsylvania, the US.

Viatris Inc Key Recent Developments

  • Mar 31, 2023: Medicines Patent Pool broadens access to generic injectable PrEP for HIV
  • Feb 27, 2023: Viatris Reports Strong Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Financial Guidance
  • Feb 27, 2023: Viatris announces appointment of Scott A. Smith as CEO Effective April 1 2023
  • Feb 15, 2023: Viatris to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Viatris Inc - Key Facts
  • Viatris Inc - Key Employees
  • Viatris Inc - Key Employee Biographies
  • Viatris Inc - Major Products and Services
  • Viatris Inc - History
  • Viatris Inc - Company Statement
  • Viatris Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Viatris Inc - Business Description
  • Product Category: Brands
  • Performance
  • Product Category: Complex Gx and Biosimilars
  • Performance
  • Product Category: Generics
  • Performance
  • Product Category: Other Revenues
  • Performance
  • Geographical Segment: Developed Markets
  • Target Markets
  • Performance
  • Overview
  • Geographical Segment: Emerging Markets
  • Target Markets
  • Performance
  • Overview
  • Geographical Segment: Greater China
  • Target Markets
  • Performance
  • Overview
  • Geographical Segment: JANZ
  • Target Markets
  • Performance
  • Overview
  • Geographical Segment: Other Revenue
  • Performance
  • R&D Overview
  • Viatris Inc - Corporate Strategy
  • Viatris Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Viatris Inc - Strengths
  • Viatris Inc - Weaknesses
  • Viatris Inc - Opportunities
  • Viatris Inc - Threats
  • Viatris Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Viatris Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Viatris Inc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Viatris Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Mar 31, 2023: Medicines Patent Pool broadens access to generic injectable PrEP for HIV
  • Feb 27, 2023: Viatris Reports Strong Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Financial Guidance
  • Feb 27, 2023: Viatris announces appointment of Scott A. Smith as CEO Effective April 1 2023
  • Feb 15, 2023: Viatris to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023
  • Dec 29, 2022: Viatris Announces Appointments of Scott A. Smith and Elisha W. Finney to the Company's Board of Directors
  • Nov 30, 2022: Biocon Biologics acquires biosimilars business of Viatris for $3bn
  • Nov 18, 2022: Viatris named U.S. In-House Legal Team of the Year for intellectual property litigation by LMG Life Sciences
  • Nov 10, 2022: SEC charges pharmaceutical Co. Chief Information Officer in $8 million insider trading scheme
  • Nov 08, 2022: Viatris agrees to acquire Oyster Point and Famy Life Sciences
  • Nov 07, 2022: Viatris reports strong third quarter 2022 results
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Viatris Inc, Key Facts
  • Viatris Inc, Key Employees
  • Viatris Inc, Key Employee Biographies
  • Viatris Inc, Major Products and Services
  • Viatris Inc, History
  • Viatris Inc, Other Locations
  • Viatris Inc, Subsidiaries
  • Viatris Inc, Key Competitors
  • Viatris Inc, Ratios based on current share price
  • Viatris Inc, Annual Ratios
  • Viatris Inc, Interim Ratios
  • Viatris Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Viatris Inc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Viatris Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Viatris Inc, Performance Chart (2018 - 2022)
  • Viatris Inc, Ratio Charts
  • Viatris Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Viatris Inc, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Samples

Loading
LOADING...

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Allergan Ltd
  • Merck & Co Inc
  • Aurobindo Pharma Ltd
  • Teva Pharmaceutical Industries Ltd
  • Sandoz Inc
  • GSK plc
  • Merck & Co Inc
  • Aurobindo Pharma Ltd
  • Allergan Ltd
  • Sandoz Inc
  • Teva Pharmaceutical Industries Ltd
  • GSK plc